Abstract
Determination of tumor genetic architecture based on tissue analysis yields important information on signaling pathways involved in cancer pathogenesis and plays a growing role in choosing the optimal medical management of malignancies. Specifically, the advent of next-generation sequencing has led to a rapidly evolving era of relatively inexpensive, high-throughput DNA sequencing of tumors. One such example is multiplexed tumor genotyping (ie, panel testing) of more than 2800 mutations across 50 commonly mutated cancer-associated genes. This resulting mutational landscape shows medically actionable pathogenic alterations to optimize antitumor therapy. We recently assessed the performance and outcome of targeted next-generation sequencing with archived endoscopic ultrasound fine-needle aspirates across a broad range of primary and metastatic sites with encouraging accuracy. As a result, endoscopic ultrasound has the potential to move from a test for diagnosis or confirmation of malignancy, to one in which it could facilitate the personalization of cancer-directed therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 37-41 |
Number of pages | 5 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2015 |
Keywords
- Endoscopic ultrasound fine-needle aspiration
- Individualized medicine
- Malignant cytology
- Targeted next-generation sequencing
- Theranostics
ASJC Scopus subject areas
- Hepatology
- Gastroenterology